BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Autogene cevumeran readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Autogene cevumeran\, from ClinicalTrials.
 gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06534983-11325@assetmemo.bio
DTSTAMP:20261121T004528Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Autogene cevumeran: Phase 2 readout est. (NCT06534983)
DESCRIPTION:Autogene cevumeran\, phase 2.\nStudy: A Study to Evaluate the E
 fficacy and Safety of Autogene Cevumeran With Nivolumab Versus Nivolumab A
 lone in Participants With High-risk Muscle-invasive Urothelial Carcinoma (
 MIUC)\nEstimated primary completion: 10 November 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/autogene-cevumeran#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06534983
URL:https://assetmemo.bio/drug/autogene-cevumeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05968326-11325@assetmemo.bio
DTSTAMP:20261121T004528Z
DTSTART;VALUE=DATE:20310101
DTEND;VALUE=DATE:20310102
SUMMARY:Autogene cevumeran: Phase 2 readout est. (NCT05968326)
DESCRIPTION:Autogene cevumeran\, phase 2\, Pancreatic Ductal Adenocarcinoma
 .\nStudy: A Study of the Efficacy and Safety of Adjuvant Autogene Cevumera
 n Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participan
 ts With Resected PDAC\nEstimated primary completion: 1 January 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/autogene-cevumeran#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05968326
URL:https://assetmemo.bio/drug/autogene-cevumeran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
